Mutations in mitochondrial DNA (mtDNA) in cancer cells confer resistance to apoptosis and promote...

A concept map of the paper "Cancer cell mitochondria confer apoptosis resistance and promote metastasis," by Mariola Kulawiec, Kjerstin M. Owens & Keshav K Singh. To link to this article: https://doi.org/10.4161/cbt.8.14.8751

Get Started. It's Free
or sign up with your email address
Mutations in mitochondrial DNA (mtDNA) in cancer cells confer resistance to apoptosis and promote metastasis by Mind Map: Mutations in mitochondrial DNA (mtDNA) in cancer cells confer resistance to apoptosis and promote metastasis

1. Experimental Results:

1.1. Sequencing: Whole genome sequence of mtDNA in breast cancer cell lines revealed multiple mutations

1.2. Mitochondrial Membrane Potential and ROS Levels: Analysis showed increased membrane potential but no significant change in ROS levels

1.3. Metastasis Studies: Tail-vein injection in mice demonstrated increased lung metastasis in mutant cybrids

2. Additional Findings:

2.1. Mitochondrial Dysfunction: Mitochondrial dysfunction in cancer cells is linked to altered metabolism and resistance to cell death

2.2. Cancer Metabolism: Cancer cells often exhibit the Warburg effect, preferring glycolysis over oxidative phosphorylation even in the presence of oxygen

2.3. Therapeutic Implications: Targeting mitochondral pathways could provide new strategies for cancer treatment

3. Collagen in Cancer Progression (Chapter 20):

3.1. Extracellular Matric (ECM) (Chapter 20): Collagens are major components of the ECM, providing structural support and influencing cell behavior

3.2. Tumor Microenvironment: Collagens contribute to the stiffness of the tumor microenvironment promoting cancer cell invasion and metastassis

3.3. Collagen Types: Various types of collagens (e.g.. collagen I, III, IV) are involved in cancer progression (Chapter 20)

3.4. Collagen Receptors: Cancer cells interact with collagens through receptors like integrins, which influence cell migration, proliferation, and survival (Chapter 20)

3.5. Desmoplasia: Increased collagen deposition (desmoplasia) is associated with tumor progression and poor prognosis

3.6. Protein Sorting (Chapter 15):

3.6.1. Golgi Apparatus: The Golgi apparatus plays a key role in protein sorting, glycosylation, and secretion, which are essential for collagen modification and ECM remodeling (Chapter 15)

3.6.2. Exosomes: Exosome-mediated protein sorting and secretion contribute to the transfer of collagen-modifying enzymes and other proteins that remodel the ECM and promote metastasis

4. Cell Junctions and Cadherins (Chapter 20):

4.1. Adherens Junctions (Chapter 20): Cadherins are key components of adherens junctions, which mediate cell-cell adhesion and maintain tissue architecture

4.2. E-cadherin: Loss of E-cadherin is associated with epitherlial-to-messenchymal transition (EMT), leading to increased cancer cell motility and invasion

4.3. N-cadherin (Chapter 20): Upregulation of N-cadherin promotes metastasis by enhancing cell migration and invasion

4.4. Cadherin Switch: The switch from E-cadherin to N-cadherin (cadherin switch) is a hallmark of EMT and is linked to poor prognosis

4.5. Signaling Pathways (Chapter 16): Cadhering interact with signaling pathways such as PI3K/Akt and Rho GTPases influencing cell survival, migration, and invasion

5. Signal Molecules in Cancer Metastasis (Chapter 16):

5.1. Growth Factors and Cytokines: Signal molecules like epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and interleukins promote cancer cell proliferation, survival, and metastasis

5.2. Chemokines: Chemokines such as CSCL12 and its receptor CXCR4 guide cancer cell migration and invasion

5.3. Neurotransmitters and Neuropeptides: Molecules like norepinephrine, substance P, and neuropeptide Y influence cancer progression by modulating the tumor microenvironment and promoting angiogenesis

5.4. Metabolix Signaling: Metabolites like lactate and succinate act as signaling molecules, activating pathways that support cancer cell survival and metastasis.

6. Mitochondrial DNA mutations:

6.1. Breast Cancer Cell Lines: Mutations found in mtDNA of MCF7, MDA-MB-231, and MDA-MB-435 cell lines

6.2. Specific Mutations:

6.2.1. MDA-MB-435: Mutation in the tRNALeu(CUN) gene, known to be involved in mitochondrial diseases

6.2.2. Common mutations in the D-loop region (A263G and T16519C) across all three cell lines

7. Generation of Cybrids:

7.1. Mutant Cybrids: Created by transferring mtDNA from cancer cells to p0 cells (cells devoid of mtDNA)

7.2. Wild-Type Cybrids: Created by transferring normal mtDNA from healthy donors

7.3. Validation: Western blot analysis confirmed similar mtDNA content in both mutant and wild-type cybrids

8. Apoptosis Resistance:

8.1. Mitochondrial Membrane Potential: Mutant mtDNA increases mitochondrial membrane potential without increasing reactive oxygen species (ROS) production

8.2. Etoposide Resistance: Mutant cybrids show resistance to apoptosis induced by etoposide

9. Metastasis:

9.1. Increased Metastatic Potential: Mutant cybrids exhibit higher metastatic potential compared to wild-type cybrids

9.2. Mouse Model: Metastasis to lungs observed in tail-vein injection mouse models

10. PI3/Akt Pathway Activation (Chapter 16):

10.1. Constitutive Activation: Mutant mtDNA leads to constitutive activation of the PI2/Akt pathway

10.2. Role in Metastasis: Activation of this pathway contributes to increased metastatic potential